在医药圈，宋瑞霖被一部分人视为异类，又被产业界看作是顶流。 过去四分之一世纪：他从朝堂之上，走入社会之中；他以法学背景跨界执掌医药协会，把一个没人愿交会费的边缘协会带成中国医药创新的代言人；他 常对政策提出批评建议，也积极参与官方文件的起草；他多次前往欧美考察学习，回国传递医改药改经验，为中国药企搭建出海桥梁。 回顾过去25年，他几乎经历了中国医药产业所有的重大变革， 那些已经隐入历史尘烟的争议人物、激荡往事像电影胶片一样 在他脑海中流转。 作者： 张英 封图：受访者供图 编者按：2025年，经济观察报以"我们的四分之一世纪"为年终特刊主题，旨在通过数十位时代亲历者的故事，共绘一幅属于这段岁月的集体记忆图 谱。 如果用一个词来形容他，最贴切的或许是"破壁者"。 宋瑞霖，1962年出生在北京胡同，曾在国务院法制办工作，2007年离开体制，后长期领导中国医药创新促进会（下称"药促会"），担任执行会长16 年，直至2025年6月卸任。 2025年12月中旬，经济观察报记者与宋瑞霖对谈了两个多小时，他仍像往常一样思维矫捷、敢于表达。回顾过去25年，他几乎经历了中国医药产业所 有的重大变革，那些已经隐入历史尘烟的争议人 ...

编者按： 2025 年，经济观察报以 " 我们的四分之一世纪 " 为年终特刊主题，旨在通过数十位时代亲历者的故事，共绘一幅属于这段岁月的集体记忆图谱。 0:00 在医药圈，宋瑞霖被一部分人视为异类，又被产业界看作是顶流。 过去四分之一世纪：他从朝堂之上，走入社会之中；他以法学背景跨界执掌医药协会，把一个没人愿交会费的边缘协会带成中国医药创新的代言人；他常对 政策提出批评建议，也积极参与官方文件的起草；他多次前往欧美考察学习，回国传递医改药改经验，为中国药企搭建出海桥梁。 如果用一个词来形容他，最贴切的或许是"破壁者"。 宋瑞霖，1962年出生在北京胡同，曾在国务院法制办工作，2007年离开体制，后长期领导中国医药创新促进会（下称"药促会"），担任执行会长16年，直至 2025年6月卸任。 2016年，宋瑞霖向国家药监局系统分享了他此前考察美国制药业时的发现——支撑美国医药产业创新的是三大法案：《拜杜法案》解决从实验室到市场的转 化问题；《哈奇-韦克斯曼法案》延长创新药的专利保护期，补偿因FDA审批占用的时间，不再要求仿制药进行临床试验，同时引入专利链接制度；《处方 药申报者付费法案》允许FDA收取申请费，FD ...

Core Viewpoint - Jinfang Pharmaceutical Technology (Shanghai) Co., Ltd. successfully went public in Hong Kong on September 19, 2025, with an opening price of 44 HKD, a 115.79% increase from the issue price of 20.39 HKD, resulting in a market capitalization of approximately 15.7 billion HKD [3] Company Overview - Founded in 2017, Jinfang Pharmaceutical was co-founded by top scientists Dr. Lü Qiang and Dr. Lan Jiong, and has undergone multiple rounds of financing, achieving a pre-IPO valuation exceeding 3.1 billion RMB [4][14] - The company focuses on innovative treatment solutions in oncology, autoimmune, and inflammatory diseases, aiming to fill significant clinical needs in these areas [8] Key Products and Innovations - The company's core product, GFH925 (commercially known as "Dabote"), is the first approved KRAS G12C inhibitor in China, filling a gap in targeted therapies for various cancers [9] - Another core product, GFH312, is a small molecule inhibitor targeting RIPK1, which has received FDA approval for a Phase II clinical trial in the U.S. [11] Financial Performance - Jinfang Pharmaceutical's financials reflect typical characteristics of innovative pharmaceutical companies, with significant initial investments and notable losses, but rapid revenue growth. Revenue for 2023, 2024, and the first four months of 2025 was 73.73 million, 105 million, and 82.15 million RMB, respectively [12] - The company reported losses of 508 million, 678 million, and 66.62 million RMB for the same periods, indicating a trend of increasing investment in R&D [12] Revenue Sources and Business Model - In 2023, the majority of revenue came from external licensing agreements, with a significant portion from a partnership with Innovent Biologics, although revenue from this source was zero in the first half of 2024, highlighting dependency on a few partners [13] - With the approval of Dabote in August 2024, the company is transitioning towards a revenue structure primarily based on product sales [13] Investment and Financing - Jinfang Pharmaceutical has completed seven rounds of equity financing, raising approximately 1.42 billion RMB, with notable investors including Honghui Capital, Dinghui Investment, and others [16][18] - The company plans to use the funds raised from its IPO for further development of core products GFH925 and GFH375, as well as for operational expenses [18]

Core Viewpoint - The recent volatility of the biotech company, Yaojie Ankang, in the Hong Kong stock market has raised questions about the investment value of the 18A sector, which consists of biotech companies without revenue or profit [2][12]. Group 1: Company Performance - Yaojie Ankang experienced a dramatic stock price increase of 130% on September 12, 2023, followed by a peak market capitalization of nearly HKD 1 trillion [3][5]. - The stock price surged to HKD 679.5 per share on September 16, 2023, before plummeting by 53.73% to close at HKD 192 per share, resulting in a market value loss of nearly HKD 200 billion within hours [3][5]. - Since its listing on June 23, 2023, Yaojie Ankang's stock price has increased nearly 13 times, with a cumulative increase of 1293.16% as of September 18, 2023 [5][10]. Group 2: Market Dynamics - The inclusion of Yaojie Ankang in multiple indices, including the Hang Seng Composite Index, led to significant passive fund buying, contributing to its rapid price fluctuations [6][7]. - The stock's low liquidity and small market capitalization made it susceptible to sharp price movements when large amounts of capital entered the market [7][9]. - The phenomenon of ETF arbitrage was highlighted, indicating that passive funds could inadvertently amplify stock price volatility [6][8]. Group 3: Investment Sentiment - The 18A sector has been characterized as a "wealth creation myth," with many investors questioning whether it represents a valuation bubble or a value opportunity [2][10]. - The market sentiment towards biotech companies has shifted from valuing potential to focusing on certainty, with investors now prioritizing market potential, pricing power, and cash flow capabilities [14][16]. - Despite recent downturns, there remains a belief among investors that value investing in the biotech sector will yield returns in the long run [11][12]. Group 4: Regulatory and Market Structure - The establishment of the 18A listing rules has been seen as a milestone in China's innovation drug ecosystem, allowing numerous biotech companies to access capital markets [10][13]. - Concerns have been raised about the need for index providers to adapt their rules to prevent short-term volatility from affecting stock valuations [9][16]. - The market's recognition of the biotech sector has increased, but the high technical barriers require investors to accurately assess the value of innovative drug companies [15][17].

Core Viewpoint - The innovative drug sector in the Hong Kong stock market is experiencing a significant rebound, with many stocks doubling in price this year, indicating a renewed investor interest and optimism in the sector [1][2]. Group 1: Market Performance - Over 20 innovative drug-related stocks in the Hong Kong market have seen year-to-date gains exceeding or nearing 100%, with 6 stocks more than doubling in value [1]. - Notable performers include Kelun-Biotech, Innovent Biologics, and Kintor Pharmaceutical, with respective price increases of 447.6%, 417.1%, and 406.5% compared to their issue prices [1]. - As of June 5, 2024, several companies listed under the 18A rule have shown significant stock price increases, with 52 out of 70 companies experiencing gains this year [3][4]. Group 2: Industry Dynamics - The introduction of the 18A listing rule in 2018 allowed unprofitable biotech companies to go public, which has led to a mixed performance in the sector due to previous market downturns [2][3]. - The innovative drug industry is transitioning from a focus on generic drugs to becoming a leader in global drug development, with domestic companies achieving significant advancements in drug efficacy [7]. Group 3: Financial Performance - By 2024, several 18A companies have reported substantial revenue growth, with top companies like BeiGene and Innovent Biologics seeing revenues rise from 75.89 billion yuan to 272.14 billion yuan and from 42.70 billion yuan to 94.22 billion yuan, respectively [4]. - In 2024, nine 18A companies achieved profitability, a significant improvement from 2020 when none were profitable [5]. Group 4: Strategic Developments - The innovative drug sector is witnessing a surge in business development (BD) deals, with 41 license-out transactions totaling $36.93 billion in the first quarter of 2025, indicating a robust international market presence [7][8]. - Companies like Hengrui Medicine have secured significant partnerships, enhancing their market position and valuation [8]. Group 5: Future Outlook - The innovative drug sector is expected to continue its upward trajectory, with many analysts predicting a valuation re-evaluation as leading companies approach profitability [6][9]. - Investment strategies should focus on the strategic direction and success probabilities of innovative drug companies, with ETFs being a viable option for new investors [10].

Core Viewpoint - Guichuang Tongqiao Medical Technology Co., Ltd. has successfully removed the "B" mark from its stock code, becoming the first 18A high-value consumable medical device company in Hong Kong to achieve this milestone, indicating its growth and profitability recognition by the capital market [3][4]. Financial Performance - In 2024, Guichuang Tongqiao achieved a revenue of 780 million RMB, representing a year-on-year growth of 48.3% [4][8]. - The net profit for the year surpassed 100 million RMB, marking the company's first annual profit [4][8]. - The gross profit margin was recorded at 71.6%, slightly down from the previous year due to price reductions from centralized procurement and proactive pricing strategies to gain market share [8]. - The net cash flow from operating activities reached 174 million RMB, an increase of 76.83% year-on-year [8]. Product Development and Market Position - The company has continuously invested in R&D, leading to successful bids for core products in multiple provincial and national procurement rounds in 2024 [4]. - Key products include the Tongqiao Silver Snake intracranial support catheter and ZYLOX Penguin iliac vein stent, which have gained significant market traction [4][9]. - Guichuang Tongqiao focuses on peripheral vascular intervention and neurointervention consumables, with leading products in the treatment of lower limb artery occlusive disease and deep vein thrombosis [9]. Industry Landscape - The 18A high-value consumables sector in Hong Kong has become increasingly competitive since the first listing of a medical device company under this category in December 2019 [7]. - Companies like Xianruida Medical and Peijia Medical are also emerging in this space, focusing on differentiated competition in peripheral vascular, neurointervention, and heart valve segments [7][9]. - The market is characterized by rapid technological advancements and commercialization efforts, with several companies achieving profitability and significant revenue growth [7][9]. Company Overview - Established in 2012, Guichuang Tongqiao specializes in the R&D, production, and sales of neurovascular and peripheral vascular intervention medical devices [10]. - The company aims to provide high-quality and affordable treatment solutions for cardiovascular disease patients through innovative medical device products [10]. - As of now, Guichuang Tongqiao has developed a product pipeline of 66 items, with 47 products approved for market release by NMPA, and its marketing network covers over 3,000 hospitals in China [10].